AMP 2026 Opens Press Credentials Ahead of Seattle Gathering
According to a Newswise dispatch dated September 14, the Association for Molecular Pathology has begun issuing complimentary press registration for its 2026 Annual Meeting & Expo, scheduled for November 10–14 in Seattle, with Andy Noble coordinating media credentials and only a limited pool of on-site passes available before the cutoff. For clinical laboratories tracking where analytical validation standards and regulatory frameworks are first articulated, the conference remains the most consequential annual convergence point in U.S. molecular diagnostics.
Scale of the Program
AMP 2026 will run five days and assemble what is effectively the largest working assembly of molecular diagnostics professionals in North America. The Association's membership now sits between 3,000 and 3,100 practitioners across the discipline's four anchor domains — infectious diseases, inherited conditions, oncology, and bioinformatics — drawn from academic centers, community hospitals, government laboratories, and industry. The Seattle program reflects that breadth: more than 200 exhibiting companies, 60 educational sessions, and over 500 poster presentations, bracketed by corporate-sponsored workshops and plenary sessions oriented toward the frontier of precision medicine. Qualifying educational tracks are calibrated for pathologists, clinical laboratory directors, basic and translational scientists, technologists, and trainees, making the venue a stratification engine for both clinical practice guidelines and emerging biomarker paradigms.
The Field at an Operational Inflection
The Seattle meeting lands as molecular pathology completes its structural migration from research tool to clinical standard of care. A parallel forum held earlier in September in Shenzhen — ICG21·MP, convened jointly by the Guangdong Precision Medicine Application Association and BGI Genomics — captured the same transition in real time. According to coverage of that event, speakers including Professor Ouyang Nengtai of Sun Yat-sen Memorial Hospital and Li Guibo of BGI Genomics' Oncology Pathology Program framed the current moment around two technological leaps: the Human Genome Project, which established a frame of reference for gene sequencing, and the maturation of high-throughput next-generation sequencing, which extended variant detection across the genome. The next stratum, both speakers argued, lies in single-cell and spatial omics, where tumor heterogeneity and microenvironmental context can be resolved at cellular resolution rather than as sample averages — a shift with direct implications for how laboratories will design validation cohorts and interpret multiplex immunofluorescence outputs.
What Laboratories Should Prepare For
For hospital pathology departments and reference laboratories, AMP 2026 will function as the primary dissemination venue for forthcoming regulatory expectations, tier-1 evidence reviews, and revisions to clinical practice guidelines affecting molecular test menus. Press materials will be distributed electronically to credentialed writers and editors at print, online, and broadcast outlets; in-person attendance requires media credentials or a letter of assignment, plus qualifying identification on arrival. Laboratories planning editorial coverage of emerging analytical validation standards, LDT oversight developments, and reimbursement shifts should lock in remote or on-site access before the limited on-site pass allocation closes in the weeks ahead of the November window.